Literature DB >> 14614137

Human adipocytes secrete mineralocorticoid-releasing factors.

M Ehrhart-Bornstein1, V Lamounier-Zepter, A Schraven, J Langenbach, H S Willenberg, A Barthel, H Hauner, S M McCann, W A Scherbaum, S R Bornstein.   

Abstract

Obesity has become an epidemic problem in western societies, contributing to metabolic diseases, hypertension, and cardiovascular disease. Overweight and obesity are frequently associated with increased plasma levels of aldosterone. Recent evidence suggests that human fat is a highly active endocrine tissue. Therefore, we tested the hypothesis that adipocyte secretory products directly stimulate adrenocortical aldosterone secretion. Secretory products from isolated human adipocytes strongly stimulated steroidogenesis in human adrenocortical cells (NCI-H295R) with a predominant effect on mineralocorticoid secretion. Aldosterone secretion increased 7-fold during 24 h of incubation. This stimulation was comparable to maximal stimulation of these cells with forskolin (2 x 10(-5) M). On the molecular level, there was a 10-fold increase in the expression of steroid acute regulatory peptide mRNA. This effect was independent of adipose angiotensin II as revealed by the stimulatory effect of fat cell-conditioned medium even in the presence of the angiotensin type 1 receptor antagonist, valsartan. None of the recently defined adipocytokines accounted for the effect. Mineralocorticoid-stimulating activity was heat sensitive and could be blunted by heating fat cell-conditioned medium to 99 degrees C. Centrifugal filtration based on molecular mass revealed at least two releasing factors: a heat sensitive fraction (molecular mass >50 kDa) representing 60% of total activity, and an inactive fraction (molecular mass <50 kDa). However, the recovery rate increased to 92% when combining these two fractions, indicating the interaction of at least two factors. In conclusion, human adipocytes secrete potent mineralocorticoid-releasing factors, suggesting a direct link between obesity and hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614137      PMCID: PMC283571          DOI: 10.1073/pnas.2336140100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

Review 1.  Obesity as a medical problem.

Authors:  P G Kopelman
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

2.  Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults.

Authors:  J He; L G Ogden; S Vupputuri; L A Bazzano; C Loria; P K Whelton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  Local renin-angiotensin system is involved in K+-induced aldosterone secretion from human adrenocortical NCI-H295 cells.

Authors:  U Hilbers; J Peters; S R Bornstein; F M Correa; O Jöhren; J M Saavedra; M Ehrhart-Bornstein
Journal:  Hypertension       Date:  1999-04       Impact factor: 10.190

Review 4.  Neuroendocrine abnormalities in visceral obesity.

Authors:  P Björntorp; R Rosmond
Journal:  Int J Obes Relat Metab Disord       Date:  2000-06

5.  Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients.

Authors:  P Dessì-Fulgheri; R Sarzani; P Tamburrini; A Moraca; E Espinosa; G Cola; L Giantomassi; A Rappelli
Journal:  J Hypertens       Date:  1997-12       Impact factor: 4.844

6.  Lymphocytes stimulate dehydroepiandrosterone production through direct cellular contact with adrenal zona reticularis cells: a novel mechanism of immune-endocrine interaction.

Authors:  G W Wolkersdörfer; T Lohmann; C Marx; S Schröder; R Pfeiffer; H D Stahl; W A Scherbaum; G P Chrousos; S R Bornstein
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

Review 7.  Secretory, endocrine and autocrine/paracrine function of the adipocyte.

Authors:  S Kim; N Moustaid-Moussa
Journal:  J Nutr       Date:  2000-12       Impact factor: 4.798

8.  Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity.

Authors:  M MacCario; S Grottoli; L Divito; R Rossetto; F Tassone; C Ganzaroli; S E Oleandri; E Arvat; E Ghigo
Journal:  Clin Endocrinol (Oxf)       Date:  2000-10       Impact factor: 3.478

9.  Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women.

Authors:  M Maccario; E Mazza; J Ramunni; S E Oleandri; P Savio; S Grottoli; R Rossetto; M Procopio; C Gauna; E Ghigo
Journal:  Clin Endocrinol (Oxf)       Date:  1999-05       Impact factor: 3.478

10.  Aldosterone in obesity.

Authors:  T L Goodfriend; B M Egan; D E Kelley
Journal:  Endocr Res       Date:  1998 Aug-Nov       Impact factor: 1.720

View more
  113 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 2.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

3.  Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules.

Authors:  S Schinner; F Ulgen; C Papewalis; M Schott; A Woelk; A Vidal-Puig; W A Scherbaum
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

4.  A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism.

Authors:  G A Kline; J L Pasieka; A Harvey; B So; V C Dias
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 5.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

6.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 7.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

8.  Increased aldosterone among HIV-infected women with visceral fat accumulation.

Authors:  Janet Lo; Sara E D Looby; Jeffrey Wei; Gail K Adler; Steven K Grinspoon
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

Review 9.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 10.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.